SIBN
Company Description
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.93M | 167.18M | 138.89M | 106.41M | 90.15M | 73.39M | 67.30M | 55.38M | 47.98M | 42.10M | 41.17M | 40.05M |
| Net Income | (18.91M) | (30.91M) | (43.34M) | (61.26M) | (56.57M) | (43.70M) | (38.40M) | (17.45M) | (23.04M) | (20.59M) | (28.15M) | (27.81M) |
| EPS | -0.44 | -0.75 | -1.13 | -1.79 | -1.71 | -1.50 | -1.72 | -1.10 | -1.66 | -1.33 | -1.17 | -10.42 |
| Free Cash Flow | (9.09M) | (22.92M) | (26.51M) | (51.16M) | (45.92M) | (33.22M) | (34.07M) | (15.46M) | (18.01M) | (17.19M) | N/A | N/A |
| FCF / Share | -0.21 | -0.55 | -0.69 | -1.50 | -1.39 | -1.14 | -1.38 | -0.97 | -1.30 | -1.11 | N/A | N/A |
| Operating CF | (675,000) | (12.43M) | (18.71M) | (41.66M) | (39.53M) | (30.66M) | (31.63M) | (14.52M) | (17.53M) | (16.75M) | N/A | N/A |
| Total Assets | 238.56M | 230.44M | 230.43M | 157.55M | 190.51M | 223.14M | 117.01M | 138.52M | 35.83M | 39.44M | N/A | N/A |
| Total Debt | 1.12M | 37.48M | 38.99M | 39.43M | 40.48M | 39.45M | 39.22M | 38.96M | 38.70M | 29.31M | N/A | N/A |
| Cash & Equiv | 42.24M | 34.95M | 33.27M | 20.72M | 63.42M | 53.58M | 10.44M | 25.12M | 22.41M | 27.90M | N/A | N/A |
| Book Value | 177.53M | 166.96M | 169.38M | 98.30M | 134.42M | 169.36M | 63.01M | 90.19M | (129.38M) | (108.73M) | N/A | N/A |
| Return on Equity | -0.11 | -0.19 | -0.26 | -0.62 | -0.42 | -0.26 | -0.61 | -0.19 | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.59M | 56.35M | 48.66M | 48.63M | 47.29M | 49.00M | 40.34M | 39.97M | 37.87M | 38.86M | 34.01M | 33.30M |
| Net Income | (4.33M) | (1.65M) | (4.57M) | (6.15M) | (6.54M) | (4.50M) | (6.58M) | (8.94M) | (10.90M) | (10.98M) | (10.02M) | (11.21M) |
| EPS | -0.10 | -0.04 | -0.11 | -0.14 | -0.15 | -0.11 | -0.16 | -0.22 | -0.27 | -0.27 | -0.25 | -0.30 |
| Free Cash Flow | (3.44M) | 440,000 | (620,000) | (1.93M) | (6.98M) | (1.09M) | (2.73M) | (9.45M) | (9.65M) | (3.39M) | (3.49M) | (6.30M) |
| FCF / Share | -0.08 | 0.01 | -0.01 | -0.05 | -0.16 | -0.03 | -0.07 | -0.23 | -0.24 | -0.08 | -0.09 | -0.17 |
| Operating CF | (2.36M) | 1.73M | 2.33M | 173,000 | (4.91M) | 1.18M | 302,000 | (6.33M) | (7.57M) | (2.30M) | (2.07M) | (3.59M) |
| Total Assets | 242.72M | 238.56M | 234.27M | 230.92M | 227.28M | 230.44M | 227.00M | 223.84M | 223.71M | 230.43M | 230.88M | 233.82M |
| Total Debt | 7.35M | 1.12M | 36.84M | 36.93M | 37.15M | 37.48M | 38.54M | 41.38M | 38.73M | 38.99M | 39.29M | 39.59M |
| Cash & Equiv | 33.53M | 42.24M | 26.49M | 34.15M | 41.19M | 34.95M | 30.23M | 25.58M | 32.04M | 33.27M | 53.49M | 110.81M |
| Book Value | 178.94M | 177.53M | 172.13M | 170.34M | 167.26M | 166.96M | 164.97M | 164.73M | 165.54M | 169.38M | 173.60M | 177.41M |
| Return on Equity | -0.02 | -0.01 | -0.03 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.07 | -0.06 | -0.06 | -0.06 |